LifeMD (NASDAQ:LFMD) Upgraded at Mizuho

Mizuho upgraded shares of LifeMD (NASDAQ:LFMD) from a neutral rating to an outperform rating in a research report sent to investors on Monday morning, Marketbeat Ratings reports. They currently have $8.00 price target on the stock, up from their previous price target of $6.00.

Other equities analysts have also issued reports about the stock. Weiss Ratings restated a “sell (e+)” rating on shares of LifeMD in a report on Monday, December 29th. Loop Capital set a $10.00 target price on shares of LifeMD in a report on Thursday, March 12th. B. Riley Financial decreased their price target on LifeMD from $12.00 to $10.00 and set a “buy” rating on the stock in a research note on Tuesday, November 18th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of LifeMD in a research note on Tuesday, March 10th. Finally, Zacks Research upgraded LifeMD from a “strong sell” rating to a “hold” rating in a report on Friday, December 19th. Seven investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $9.14.

LifeMD Trading Down 7.4%

NASDAQ LFMD opened at $4.11 on Monday. The stock has a fifty day simple moving average of $3.35 and a 200-day simple moving average of $4.49. The stock has a market cap of $197.16 million, a PE ratio of 15.81 and a beta of 1.92. LifeMD has a twelve month low of $2.56 and a twelve month high of $15.84.

LifeMD (NASDAQ:LFMD) last issued its quarterly earnings data on Monday, March 9th. The company reported ($0.04) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.01) by ($0.03). The company had revenue of $46.87 million during the quarter, compared to analysts’ expectations of $48.57 million. LifeMD had a net margin of 6.58% and a negative return on equity of 83.93%. Research analysts predict that LifeMD will post -0.56 EPS for the current year.

Hedge Funds Weigh In On LifeMD

Institutional investors have recently modified their holdings of the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in shares of LifeMD by 4.7% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 49,647 shares of the company’s stock worth $270,000 after acquiring an additional 2,235 shares during the period. Tower Research Capital LLC TRC boosted its holdings in LifeMD by 110.4% in the second quarter. Tower Research Capital LLC TRC now owns 4,674 shares of the company’s stock valued at $64,000 after purchasing an additional 2,452 shares during the period. SG Americas Securities LLC grew its stake in LifeMD by 13.8% during the 4th quarter. SG Americas Securities LLC now owns 25,298 shares of the company’s stock worth $86,000 after purchasing an additional 3,061 shares in the last quarter. Invesco Ltd. grew its stake in LifeMD by 18.8% during the 4th quarter. Invesco Ltd. now owns 24,464 shares of the company’s stock worth $83,000 after purchasing an additional 3,870 shares in the last quarter. Finally, Rhumbline Advisers increased its holdings in LifeMD by 8.7% during the 2nd quarter. Rhumbline Advisers now owns 53,589 shares of the company’s stock worth $730,000 after purchasing an additional 4,281 shares during the period. Institutional investors and hedge funds own 35.52% of the company’s stock.

About LifeMD

LifeMD (NASDAQ: LFMD) is a U.S.-based telehealth company that delivers on-demand, membership-based virtual healthcare services. Through its digital platform and mobile applications, LifeMD connects patients with board-certified healthcare providers for diagnosis, treatment and ongoing management of a range of acute and chronic conditions. The company’s core offering centers on personalized care plans supported by prescription fulfillment, lab testing and prescription delivery services.

LifeMD’s service portfolio spans several specialty areas, including men’s health, hormonal therapy, weight management and primary care.